Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...
Investor's Business Daily on MSN3d
Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention FundingGilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback